BioMed Research International
Volume 2015 (2015), Article ID 845340, 14 pages
http://dx.doi.org/10.1155/2015/845340

Review Article

Chemotherapy and Chemoprevention by Thiazolidinediones

Eleonore Fröhlich1,2 and Richard Wahl¹

¹Internal Medicine, Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Department IV, University of Tuebingen, Otfried-Muellerstrasse 10, 72076 Tuebingen, Germany
²Center for Medical Research, Medical University of Graz, Stiftingtalstraße 24, 8010 Graz, Austria

Received 31 May 2014; Revised 29 July 2014; Accepted 27 August 2014

Academic Editor: Viroj Boonyaratanakornkit

Copyright © 2015 Eleonore Fröhlich and Richard Wahl. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Thiazolidinediones (TZDs) are synthetic ligands of Peroxisome-Proliferator-Activated Receptor gamma (PPAR). Troglitazone, rosiglitazone, and pioglitazone have been approved for treatment of diabetes mellitus type II. All three compounds, together with the first TZD ciglitazone, also showed an antitumor effect in preclinical studies and a beneficial effect in some clinical trials. This review summarizes hypotheses on the role of PPAR in tumors, on cellular targets of TZDs, antitumor effects of monotherapy and of TZDs in combination with other compounds, with a focus on their role in the treatment of differentiated thyroid carcinoma. The results of chemopreventive effects of TZDs are also considered. Existing data suggest that the action of TZDs is highly complex and that actions do not correlate with cellular PPAR expression status. Effects are cell-, species-, and compound-specific and concentration-dependent. Data from human trials suggest the efficacy of TZDs as monotherapy in prostate cancer and glioma and as chemopreventive agent in colon, lung, and breast cancer. TZDs in combination with other therapies might increase antitumor effects in thyroid cancer, soft tissue sarcoma, and melanoma.

1. Introduction

Glitazones, also called thiazolidinediones (TZDs), are five-membered carbon ring molecules containing two heteroatoms (nitrogen and sulfur). One carbonyl group in the thiazole at position 4 and another at position 2 make the heterocyclic compound a thiazolidine-2,4-dione [1]. TZDs are ligands of the Peroxisome Proliferator Activated Receptor gamma (PPAR), a nuclear receptor inducing upregulation of specific genes that decrease insulin resistance, inflammation, VEGF-induced angiogenesis, proliferation, and leptin levels, inducing differentiation of adipocytes, and increasing adiponectin levels. This spectrum of actions led to the approval of TZDs for treatment of diabetes mellitus type II. TZDs differ according to the substitution at C5 (Figure 1).

Figure 1: Chemical formulae of the most common TZDs with antitumor action.

Ciglitazone (CIGLI) is the prototype of all TZDs but has never been approved for medication of diabetes mellitus because its clinical activity was too weak. Troglitazone (TRO) was the first TZD approved for treatment of diabetes mellitus in 1997 [2]. The compound showed beneficial effects on glucose levels, insulin sensitivity, and free fatty acid concentration but was withdrawn from the market in 2000 due to severe hepatotoxicity. The second TZD, rosiglitazone (ROSI), has been banned in Europe and restricted in the USA because of increased cardiovascular morbidity. Also the use of pioglitazone (PIO) as the third TZD with antidiabetic action is restricted due to concerns about a potential facilitation of bladder cancer development. The fourth substance with an antidiabetic profile, rivoglitazone, is still under investigation [3]. Reasons for the troubled history of antidiabetic TZDs are manifold and appear to be due to the highly pleiotropic action of these PPAR agonists and crosstalk of PPAR with other signaling pathways.

In addition to diabetes mellitus treatment, ligands to PPAR could also be exploited for treating other diseases, for instance, in cancer treatment. This idea originated from the finding that PPAR is involved in cell proliferation and PPAR expression levels change from normal to transformed tissues. Effects of PPAR activation are ligand-specific. TZDs with potent PPAR agonist activity can display, like rivoglitazone, strong antidiabetic activity, or, like efatutazone (EFA), predominantly antitumor effects. TZDs, such as netoglitazone, can also activate other PPARs and cause antitumor effects [4]. This review will focus on the effects of selective PPAR TZDs in tumors.

2. Role of PPAR Expression in Neoplasms

PPAR expression compared to normal tissue tends to be increased in precursor lesions and differentiated tumors and decreased in the poorly differentiated cancers. This pattern has been reported for instance for gastric, ureteric, and breast cancer [5–7]. In ovarian cancer, however, PPAR levels independent from tumor differentiation are increased [8]. Upregulation of PPAR may be an early event in tumorigenesis and a marker for differentiated cancer lesions [9]. Methylation (silencing) of the PPAR promotor, which is detected in 30% of colorectal tumors, however, correlated with poor prognosis [10]. Studies linking tumor prognosis and PPAR expression were mainly based on immunohistochemical detection of the PPAR antigen in paraffin-embedded tissue. Since antigenicity is low and may decrease during storage of the paraffin samples, the absence of PPAR staining in archival tissues may be a false negative due to methodological problems [11].

Identification of the contribution of PPAR to tumor development and progression is further complicated by crosstalk with other pathways. Akt phosphorylation in the endometrium, for instance, is directly regulated by PPAR and indirectly through induction of PTEN by PPAR, where PTEN decreases p-Akt via inhibition of PI3K [12].

3. Mechanism of Antitumor Action by TZDs

Although all TZDs are PPAR ligands, the observed antitumor effects can only be explained in part by genomic PPAR activation. Genomic activation is defined as the binding of a nuclear receptor to a response element, which activates the transcription of certain genes. The process is also termed transactivation. Another DNA-mediated effect is transrepression, which describes the binding of receptors to transcription factors (e.g., nuclear factor kappa B (NFB) or activator protein 1 (AP-1)).

PPAR ligands trigger a conformational change of the PPAR receptor that attracts transcriptional coactivators of the steroid receptor coactivator family. Once activated by ligand binding, the PPAR receptor forms heterodimers with the retinoid X-receptor and transcription is initiated. Transcriptional activation may result in decreased proliferation, migration and inflammation and increased differentiation and apoptosis (Figure 2). Inflammatory effects are usually mediated by transrepression [13].

Figure 2: Effects of TZDs on apoptosis, migration, invasion, and proliferation of cancer cells and on inflammation. In some ellipses, only one representative is listed; Bax and p53 react similarly, as well as p27 and p21. MMPs represents MMP-2 and MMP-9 and Cyclin E represents cyclin D1, cyclin B1, CDK2, and CDK4. Abbreviations: EGF: epithelial growth factor receptor; PPRE: PPAR response element, Surv: survivin, E-cad: E-cadherin, b-cat: -catenin, Cytok: cytokines.

Figure 2 illustrates the variety of pathways influenced by genomic activation of PPAR by TZDs, resulting in downregulation of migration, proliferation, inflammation, and invasion and in upregulation of apoptosis. Common mechanisms involve influence on EGF signaling, cyclins, Ki-67, c-myc, cyclin-dependent kinases, p53 and PTEN expression, adhesion proteins, metalloproteinases, and cytokines [14–19].

Hormone-dependent cancers react through different mechanisms to TZDs depending on the hormone receptor status. In androgen-dependent prostate carcinoma, for instance, CIGLI downregulated aromatase activity, while in androgen-independent tumors proliferation was reduced [20].

Different TZDs may act by different mechanisms; while CIGLI downregulated cyclin D1 and upregulated p21 by PPAR independent pathways, ROSI used PPAR signaling to induce these effects in androgen-independent prostate carcinoma cells [21].

The description of all mechanisms of TZDs is beyond the scope of this review but one important signaling pathway for tumor cells and for surrounding tissue (tumor microenvironment) each illustrates the variety of PPAR effects. Tumor biology is not only determined by tumor cells but to a high extent by properties of stromal cells in the tumor microenvironment. Among the diverse cells in the tumor stroma (endothelial cells, cancer-associated fibroblasts, leukocytes, myofibroblasts, and mesenchymal stem cells), tumor-associated macrophages play the most decisive role in tumor progression [22].

For tumor cells, signaling by Epidermal Growth Factor receptor (EGF-receptor, Figure 2) is highly relevant. The signaling cascade of the EGF-receptor involves the ERK cascade, consisting of Ras-Raf-MEK1/MEK2-ERK1/ERK2 and is seen in several cancer types [23]. ERK may phosphorylate PPAR and reduce its genomic activity. This effect occurs in cancer cell lines and a variety of normal cells alike [24]. TRO, for example, was reported to bind to the EGF receptor and trigger its internalization in EGF-receptor transfected endothelial cells [25]. This action is an example of nongenomic effects of TZDs since no ligand binding to response element occurred.

Normal macrophages can transform into tumor-associated macrophages under stimulation of PPAR ligands [26]. ROSI decreased activation of macrophages and thereby reduced inflammation in nondiabetic patients with symptomatic carotid artery stenosis [27]. In murine macrophages, these effects are mediated by interaction of PPAR with NfB [28]. In these effects, transrepression appears to be the main mechanism.

Finally, MEK1 action by ROSI may lead to nuclear export and cytoplasmic retention of PPAR and off-DNA interaction with proteins in MEK1-GFP and PPAR (wild-type and mutant) cotransfected HEK-293 cells [29]. In this effect no genomic action of TZDs was involved.

4. Therapeutic Efficacy of TZDs in Specific Cancers

Decrease of cell proliferation, cytotoxicity, and proapoptotic effects induced by CIGLI, TRO, ROSI, and PIO has been reported in a variety of cell lines (sarcoma, melanoma, glioblastoma, breast carcinoma, colorectal cancer, gastric cancer, pancreatic cancer, prostate, bladder cancer, hepatic cancer, thyroid cancer, ovarian cancer, endometrial cancer, and lung cancer cells), which will not be listed in detail. Based on promising cellular action, animal experiments and clinical trials have been conducted in several common cancers.

EFA, which was developed as a chemostatic rather than an antidiabetic drug, has also been studied in some of these cancers. EFA is 500x more potent an activator of PPAR than TRO and 50x stronger than ROSI. EFA was studied in a preclinical murine model for breast cancer based on BRCA1 (BReast CAncer 1) deficiency. In the MMTV-Cr    model, exon 11 of the BRCA1 gene is deleted by Mouse Mammary Tumor Virus (MMTV)-Cre transgene. The deletion is accompanied by loss of one germline copy of TP53. EFA reduced the incidence of noninvasive and well-differentiated tumors in this model [30].

Cell proliferation and xenograft size of pancreatic, anaplastic thyroid, and colorectal cancer were reduced by EFA administration [31].

Based on these promising preclinical effects, phase I trials were initiated either as monotherapy or in combination with other compounds. After monotherapy with EFA, stable disease was induced in 10/22 patients with advanced liposarcoma [14]. A phase 1 study evaluating the combination of bexarotene with EFA in solid tumors is currently recruiting patients (NCT01504490).

The first trial of antitumor effects of the antidiabetic TZDs was conducted in three liposarcoma patients, where decrease of proliferation with TRO has been reported [32]. No beneficial effects, however, were obtained in a trial with ROSI in 9 liposarcoma patients [33]. Despite the negative outcome of this trial, another phase II trial on ROSI is ongoing (NCT00004180; http://www.cancer.gov/clinicaltrials/).

TZDs showed variable efficacy in studies of common cancers using xenograft and transgenic mouse models, in case studies and clinical trials (an overview is provided in Table 1).

Table 1: Relationship between protective role of PPAR expression and efficacy of TZDs in therapy.

Cancer type
Role of PPAR
TZD
Experimental model
Result
Reference

PIO
Xenograft (HT-29) in mice with APC mutation, sc
Increased tumor growth
[41]

Colon
/

Azoxymethane-induced murine tumors
Reduced tumor growth
[39]

TRO
HT-29 xenografts, sc
Reduced tumor growth and metastasis
[40]

Metastatic colon cancer, 25 patients
All progressive disease
[43]

Lung
/
ROSI
Chemically-induced mouse model
Decrease in adenoma formation
[46]

ROSI
LMM3 injection into mice, sc
Decreased tumor growth
[48]

Breast

Chemically induced rat model
Decreased tumor growth and incidence
[49]

TRO
Advanced chemotherapy breast refractory cancer, 22 patients
No CR or PR, 3 SD
[50]

ROSI
Early stage breast cancer, 38 patients
No decrease in proliferation
[51]

PIO
PC3 xenografts, sc.
Decrease of bone-invasive potential
[53]

Prostate

TRO
Advanced prostate carcinoma, 41 patients
Stabilization of PSA levels
[54]

ROSI
Recurrent prostate carcinoma, 1 patient
Delayed increase of PSA levels
[55]

Glioma

PIO
LN229 orthotopic xenografts
Reduced tumor volume, invasion
[58]

Chemorefractory glioma, 14 patients
Disease stabilization (29%)
[59]

Melanoma

CIGLI
A375 xenografts, sc.
Growth inhibition, pro-apoptotic effects
[62]

PIO
Transgenic mouse model (PPAR fusion protein/PTEN deletion)
Decreased tumor growth and metastasis
[106]

Thyroid

ROSI
Transgenic mouse model (Thyroid hormone receptor- negative)
Delayed progression
[107]

Metastatic thyroid cancer, 1 patient
Decrease in metastasis size
[109]

PPAR expression on tumor progression: promotion: ; protection: ; no effect: ; CR: complete response; PR: partial response; SD: stable disease; sc: subcutaneous implantation of tumor cells.

4.1. Colorectal Cancer

Studies on human tumor samples support the hypothesis that PPAR expression has protective effects in colorectal cancer [34]; patients with PPAR expression usually showed a better prognosis [11]. Accordingly, reduction of -catenin and PPAR was associated with high numbers of tumor-associated macrophages, increased metastasis, and poor survival [35]. On the other hand, loss of function point mutations of the PPAR gene and polymorphisms in PPAR genes were encountered in 8% of colorectal carcinoma patients, but some studies on PPAR expression in colorectal samples did not find any relation of PPAR immunoreactivity and tumor parameters [36, 37]. The role of PPAR activation in the progression of malignant lesions is questioned by the fact that heterozygous and homozygous intestinal-specific PPAR deficiency promoted tumor formation [38]. This suggests that murine models might not be representative for the study of TZDs in colorectal cancer.

Consistent with the unclear role of PPAR in tumor samples, TZDs showed variable effects in vivo. PPAR activation inhibited xenograft growth in mice and PPAR agonists reduced the number of aberrant cryptal foci in chemically induced inflammatory bowel disease in mice [39, 40]. On the other hand, PIO induced increased polyp numbers in mice with APC mutation, prone to developing colon adenoma (), not in wild-type mice, suggesting that, under certain genetic conditions, TZDs could also promote colon cancer development [41]. The disparate results might be explained by in vitro studies in colon cancer cell lines showing that the level of PPAR expression correlated to cells’ sensitivity to proliferation inhibition [42].

A phase II trial with TRO did not increase progression-free survival in 25 colorectal cancer patients [43].

4.2. Lung Cancer

PPAR expression in well-differentiated lung adenocarcinoma was higher than in poorly differentiated tumors, suggesting that it promotes tumor formation but is not a marker for aggressive growth [44]. In another study, expression was linked to poor prognosis, showing the opposite trend [45]. ROSI decreased progression of chemically induced murine cancer model [46].

4.3. Breast Cancer

In breast cancer PPAR mRNA levels did not correlate with nodal involvement and tumor grade but significantly lower PPAR levels were seen in large metastatic tumors, patients with local recurrence and poor survival [47]. Despite the fact that samples of aggressive tumors showed increased PPAR expression, TZDs displayed moderate positive effects in breast cancer models. ROSI reduced tumor growth in a chemically induced rat and in a syngenic murine tumor model [48, 49]. Both in patients with advanced breast carcinoma and in patients with early mammary cancer treatment with TZDs did not cause therapeutic effects [50, 51].

4.4. Prostate Cancer

In the majority of prostate cancers (73%), immunoreactivity and expression of PPAR correlated inversely with tumor size and PSA levels [52]. Data obtained in prostate cancer xenografts as well as results from a phase II trial and a case report showed efficacy of PIO and TRO [53–55].

4.5. Glioblastoma

No correlation of PPAR expression has been established with glioma [56]. Diabetes mellitus patients under TZD medication, however, showed lower incidence of high-grade glioma than the control group (patients with hip fractures), while survival of patients with glioma was similar in both groups [57]. Efficacy of PIO has been shown in glioma xenografts and in a phase II trial [58, 59].

4.6. Melanoma

No correlation of PPAR expression and melanoma prognosis was seen [60]. In a cohort study of diabetes mellitus patients under PIO medication, an increased hazard ratio for melanoma (1.3) was reported [61]. It is not clear whether these data represent an increased incidence of tumors because the maximum duration of follow-up was <6 years after the initiation of PIO. Studies on monotherapy with TZDs in melanoma are limited: only CIGLI was reported to inhibit growth of melanoma xenografts [62].

Higher mRNA or protein expression in well-differentiated tumors compared to poorly differentiated tumors and tumors with poor prognosis is interpreted as protective effect of PPAR in tumor development. In prostate cancer patients, protective effects of PPAR and therapeutic effect of TZDs were in line (Table 1). In glioma samples, PPAR expression was not linked to good prognosis but TZDs showed therapeutic efficacy.

5. Role of TZDs in Chemoprevention

While therapeutic efficacy of monotherapy with TZDs was relatively low, data obtained from meta-analysis of diabetes studies as well as in vitro data suggested that TZDs could be efficient in chemoprevention (Table 2).

Table 2: Summary of data on chemopreventive effects of TZDs in animal and human epidemiological studies.

Cancer type
Role of PPAR expression
TZD
Experimental model
Result
Reference

PIO
Chemically-induced rat cancer model
Reduction of tumor incidence
[121]

Colon
/

Transgenic murine cancer model (nonsense mutation in the adenomatous polyposis coli)
Increase of tumor incidence
[122]

TRO
Chemically-induced rat cancer model
Reduction of tumor incidence
[123]

ROSI
Meta-analysis of diabetes trials
Reduced colon cancer incidence
[64]

Lung
/
PIO
Chemically induced murine cancer model
Reduction of tumor incidence
[72]

PIO
Observational study
Reduced lung cancer incidence
[63]

Breast

PIO
Meta-analysis of diabetes trials
Reduced breast cancer incidence
[64]

Liver

PIO
Chemically induced rat cancer model
Reduced tumor incidence
[73]

Endometrium

ROSI
Transgenic murine cancer model
Reduced tumor incidence
[12]

Oral (squamous cancer)

PIO
Transgenic rat cancer model
Reduced tumor incidence
[77]

TRO
Chemically induced rat cancer model
Reduced tumor incidence
[78]

PPAR expression on tumor progression: promotion: ; protection: .

5.1. Data from Diabetes Trials

Medication with TZDs for >1 year decreased the incidence of head and neck cancers by 40% and lung cancer by 33% in diabetes mellitus patients [63]. The reduction of lung cancer reached 75% in the African-American population. The reduction was specific for lung cancer, as prostate and colorectal cancer incidence was not changed. Of note, in this study, patients with preexisting malignancies were excluded. The largest meta-analysis on cancer incidence and cancer mortality included data of 46 trials. The number of malignancies was disclosed in 28/33 trials with ROSI and in 18/33 trials with PIO [64]. This meta-analysis reported less cancer cases (342 versus 457) in patients treated with TZDs compared to other medications. Overall, treatment with TZDs was associated with a significantly lower incidence of cancer cases (Mantel-Haenszel odds ratio (MH-OR) 0.85; ). For ROSI this effect was significant for colorectal cancer (MH-OR 0.63; ). PIO treatment significantly reduced the incidence of breast cancer (MH-OR 0.28; ). An increase in the incidence of bladder cancer by PIO treatment was not seen (MH-OR 2.05; ), but cancer mortality was increased upon TZD treatment. Since this mortality most probably is due to preexisting cancers, the question remains whether treatment with TZDs could promote the growth of already existing malignant lesions.

5.2. In Vitro Differentiation Studies

Morphological differentiation (duct formation in collagen gels) increased in pancreatic carcinoma cells treated with TRO [65] and increases of villin and mucin mRNA were observed in colon cancer cell lines [66]. ROSI induced PTEN expression in Caco-2 cells and restored glandular morphogenesis [67]. It increased tyrosinase expression, an indication for differentiation, in a melanoma cell line [68]. ROSI also caused reversal of epithelial-mesenchymal transition in anaplastic thyroid cancer cell lines and increased expression of thyroglobulin, TSH receptor, sodium-iodide symporter, and thyroperoxidase mRNA [69]. CIGLI induced brain tumor stem cell differentiation [70]. In cultures of metaplastic urothelial cells, differentiation markers were increased after treatment with TRO [71].

5.3. TZD Effects in Animal Studies

PIO prevented lung tumor development in carcinogen-induced mouse models [72]. In a similar manner, PIO protected rats against chemically-induced (diethylnitrosamine and acetylaminofluorene) hepatocarcinogenesis [73]. PPAR could play a tumor-promoting role in hepatoma, because expression is significantly reduced in hepatocellular carcinoma with poor prognosis [74]. A similar situation is seen in endometrium carcinoma, where benign lesions show strong PPAR immunoreactivity but malignant lesions low to absent PPAR expression [12]. Chemoprevention of endometrial cancer by ROSI was observed in PTEN heterozygous mice [75]. Increased PPAR expression was predominantly seen in less invasive oral squamous cancer [76]. Chemically-induced oral squamous carcinoma in rats was reduced by 40% through administration of PIO [77] and tongue carcinoma formation was reduced by 40% by TRO [78].

On the other hand, tumor-promoting effects of PIO were observed in the murine colon cancer model [41]. Because tumor-promoting effects were not seen in all cancer models, a model-specific effect cannot be excluded. The complex and, in part, opposing effects of TZDs on cancer development and progression can be explained by their cell-specific and species-specific action (tumor cells versus tumor environment). Effects of TZDs on immune cells may be the reason for the tumor-promoting effect of PIO in the mouse model and the reduced tumor growth in immune-compromised mice and in the azoxymethane-induced tumor model [79]. While PPAR activation may decrease proliferation of tumor cells, it may increase macrophage polarization towards the M2 phenotype (TAM) and induce anti-inflammatory effects, also mediated by PPAR activation (see Section 3)

5.4. Human Data

One phase II trial on prevention of lung, head, and neck carcinoma in 21 patients with oral leukoplakia using PIO has been completed. Fifteen patients showed partial responses, 2 stable disease and 4 patients had progressive disease (NCT00099021; http://www.cancer.gov/clinicaltrials/). Based on these promising results, another trial on prevention of lung cancer is recruiting patients (NCT00780234; http://www.cancer.gov/clinicaltrials/).

In human trials, no general correlation of the protective effect of PPAR expression against tumor progression and chemopreventive effects of TZDs was obvious. While a protective role of PPAR expression was postulated in breast tumors and TZDs also acted preventive on the development of breast cancer in humans, the chemopreventive effect on colon cancer was not consistent with a protective role of PPAR expression in tumor samples.

6. Combined Treatments of TZDs with Other Drug Compounds

6.1. In Vitro Studies

Several studies evaluated the effect of combined therapies with TZDs and other agents. A large variety of combinations of TZDs have been evaluated in vitro. The observed antitumor effects include cytotoxicity/decrease of cell viability, growth inhibition, and apoptosis (for overview see Table 3).

Table 3: Results of therapies combining TZDs with other antitumor treatments.

TZD
Additional compound
Model
Effect
Reference

Gamma-radiation
Lung carcinoma cell lines (A549, H460)
DNA damage, apoptosis
[124]

RXR- ligands (SR11237, 6-OH-11-O-hydroxyphenanthrene)
Breast carcinoma cell line (MDA-MB231), lung carcinoma cell line (Calu-3), glioblastoma cell line (U87MG), melanoma cell line (G361)
Growth inhibition; apoptosis
[125–127]

CIGLI
TNF--related apoptosis inducing ligand
Ovarian cancer cell line (HEY)
Decrease of proliferation
[128]

Lovastatin
Pancreatic carcinoma cell lines (Panc02, MIA, PACa-2), breast carcinoma cell lines (EMT6, MDA-MB-316), colon cancer cell line (C26)
Decrease of cell viability; decrease of proliferation
[129]

Phenylbutyrate
Lung carcinoma cell lines (A549, H157)
Growth inhibition
[130]

9-cis retinoic acid
Gastric carcinoma cell line (SGC7901)
Apoptosis
[131]

Cisplatin
Lung cancer cell lines (A549, H522); mesotheloma cell line (EHMES-10)
Growth inhibition
[87, 132]

Paclitaxel
Lung carcinoma cell lines (A549, H522)
Growth inhibition
[132]

RXR- ligands (bexarotene, all-trans retinoic acid)
Breast cancer cell lines (MCF-7, T-47D, ZR-75-1)
Growth inhibition
[133]

TRO
Cell signalling molecules (TRAIL, heregulin)
Ovarian cancer cell line (HEY); breast cancer cell lines (MCF-7, SKBR-3, MDA-MB-453)
Decrease of cell number; apoptosis
[128, 134]

Lovastatin
Glioblastoma cell line (DBTRG05MG), lung cancer cell line (CL1-0)
Cell cycle inhibitor expression
[135]

Aspirin
Lung cancer cell lines (CL1-0, A549)
Decrease of proliferation
[136]

Tamoxifen
Breast cancer cell line (MCF-7)
Growth inhibition
[137]

X-rays
Cervix cancer cell lines (HeLa, Me180)
Decrease of cell viability
[138]

Platinium-based compounds (cisplatin, carboplatin)
Ovarian cancer cell lines (OVCA420, OVCA429, ES), lung cancer cell lines (A549, Calu-1, H23, H596, H1650)
Growth inhibition
[85]

5-Fluorouracil
Hepatoma cell lines (BEL7402, Huh-7); colon cancer cell line (HT-29)
Decrease of cell viability, apoptosis
[82, 139]

RXR- ligands (bexarotene, 9-cis retinoic acid)
Breast cancer cell lines (MCF-7TR1, SKBR-3, T47D), colon cancer cell line (Moser)
Increase of differentiation, growth inhibition; decrease of cell viability
[80, 140]

ROSI
Cell signalling molecules (TNF-, anti-Fas IgM, Seliciclib)
Breast cancer cell line (MDA-MB-231)
Growth inhibition
[141]

Gemcitabine
Pancreas cancer cell lines (PANC-1, Panc02)
Decrease of cell viability, growth inhibition
[142]

Gefitinib
Lung cancer cell line (A549)
Growth inhibition
[83]

Herceptin
Breast cancer cell line (MCF-7)
Growth inhibition
[84]

Bortezomib
Melanoma cell lines (MV3, FemX-1, G361)
Growth inhibition
[143]

Paclitaxel
Lung cancer cell lines (A549, H522)
Growth inhibition
[132]

RXR- ligands (LG268)
Liposarcoma cells (primary)
Increase of differentiation
[81]

PIO
Statins (Simvastin, lovastatin)
Glioblastoma cell lines (U87, U138, LN405, RGII); meningeoma cell lines (IOMM-Lee, KT21-MG1)
Decrease of cell viability
[144, 145]

Gemcitabine
Pancreas cancer cell line (PANC-1)
Decrease of cell viability
[142]

2-Deoxyglucose
Prostate cancer cell lines (PC-3, LNCaP)
Decrease in tumor spheroid formation
[146]

EFA
Paclitaxel
Anaplastic thyroid carcinoma cell lines (DRO, BHT-101, ARO)
Growth inhibition
[88]

In combination treatment with RXR-α ligands, increased cellular differentiation was reported [80, 81]. Some combined therapies take advantage of the cross-talk of PPAR with other signaling pathways. For instance, the upregulation of PTEN by ROSI rendered hepatoma cells more sensitive to the action of 5-fluorouracil [82]. Based on the idea of cross-talk between the ERK and PPAR pathways, combinations of ERK inhibitors and PPAR agonists could be useful in tumors with deleterious elevation of PPAR. Experimental data corroborate such an idea: gefitinib and ROSI increased growth inhibition of lung cancer cells and increased PPAR and PTEN expression [83]. Herceptin, an antibody against the EGF-receptor HER2, sensitized breast cancer cells for the differentiating action of TRO [84].

6.2. Animal Studies

The following examples show that improved antitumor responses were also obtained in vivo: growth of lung carcinoma xenografts and of chemically-induced breast tumors was inhibited by a combination of ROSI and platinum-based compounds [85, 86]. ROSI in combination with suberoylanilidehydroxamic acid (SAHA) decreased progression of preinvasive lung cancer in a murine model by 77% [46]. Similarly, a combination of TRO and platinum-based compounds increased survival of mesothelioma-xenografted mice [87]. The combination of EFA and paclitaxel reduced the size of anaplasic thyroid carcinoma xenografts [88]. Progression of ovarian carcinoma xenografts was slower when a combination of CIGLI and cisplatin was administered. Synergistic effects were reduction of angiogenesis and increased proapoptotic effects [89]. Aerosolized budesonide and oral PIO decreased lung cancer mass by 90% in a benz(a)pyrene-induced murine lung cancer model [90].

6.3. Human Data

Phase II trials of combination with the COX-2 inhibitor rofecoxib and PIO were able to induce complete response, partial responses, or stable disease in 5/5 angiosarcoma, 1/1 hemangioendothelioma, 4/19 metastatic melanoma, 10/40 soft tissue sarcoma, and 4/14 glioma patients [59, 91, 92]. Combination of PIO with other chemostatic drugs induced one complete response and prolonged disease-free survival in 2 of 19 patients with advanced melanoma enrolled in this phase II trial [91]. These data suggest potential efficacy of TZDs combined with other compounds in melanoma. For further evaluation of comedication with TZDs in patients, a prospective phase I/II trial of PIO combined with lenalidomide, dexamethasone, and treosulfan (NCT01614301) is currently recruiting patients (http://www.cancer.gov/clinicaltrials/).

According to human trials, only soft tissue sarcoma and melanoma might be sensitive to combinations of TZDs and COX-2 inhibitors and TZDs in polytherapy, respectively.

7. Specific Role of TZDs in Differentiated Thyroid Carcinoma (DTC)

PPAR has a specific role in thyroid cancer because follicular thyroid cancer is the only known neoplasm to be associated with a PPAR fusion gene product [93]. PAX8/PPAR is expressed in 30–35% of follicular thyroid carcinoma and 2–13% of follicular adenomas [94]. This chimeric protein is the result of a genetic translocation between chromosomes 2 and 3 and can activate the PPAR response element and induce proliferation. The mutation acts both as a gain and loss of function mutant in thyroid cancer and determines thyroid tumor differentiation; in more aggressive tumors gain of function predominates [93].

Thyroid cancer incidence in the United States has increased in the last thirty years not only apparently because of enhanced detection but probably also as a true increase [95]. DTC is the most common type of thyroid carcinoma, mainly in the form of papillary thyroid carcinoma, accounting for 80–90% of all thyroid cancer cases. The second-most common form of DTC is follicular thyroid cancer with 10–15% incidence. The prognosis of DTC is generally good, with a 10-year survival rate of 85% [96]. A total of 10–20% of patients develops distant metastases [97]. In this group, the 10-year survival rate drops to 40%. Recurrence in DTC, however, occurs in up to a third of patients and only 30% of patients with distant metastases respond to radioiodine (RAI) therapy with complete remission [98, 99]. First-line treatment of DTC is by total or near total removal of the thyroid and if necessary lymph node dissection (Figure 3). This is generally followed by RAI treatment for thyroid remnant ablation and elimination of metastases. In case of insufficient efficacy of this treatment, doxorubicin is initiated [100]. Because doxorubicin treatment is not highly efficient, it is expected that, in the future, differentiating therapies will play a prominent role in cancer treatment. Redifferentiating compounds include retinoids, histone deacetylase inhibitors, DNA methyltransferase inhibitors, and TZDs. Somatostatin analogues such as ⁶⁸Ga-DOTATOC are additional options for RAI-negative thyroid cancer [101].

Figure 3: Overview of treatment options for DTC. Scheme of thyroid tumor (upper left) and scintigraphy with showing lack of uptake in the lower part of the right lobe (upper right).

PIO and CIGLI did not increase differentiation in a study on the human papillary carcinoma cell line NPA [102]. In another, TRO, ROSI, and PIO showed antiproliferative, proapoptotic, and differentiating effects on DTC cells [103]; TRO could increase expression of sodium-iodide symporter in DTC lines [104] and restore radioiodine-uptake in vitro [105].

7.1. Animal Studies

PIO was effective in reducing metastatic disease in a tumor model where the effect of PAX8/PPAR fusion protein is mimicked [106]. ROSI was also able to reduce thyrocyte growth by 40% in a murine knock-in model of thyroid hormone receptor [107].

7.2. Human Data

In a small cohort of 5 patients treated with PIO for 6 months, no increase in RAI-uptake was seen [108]. Two case reports described successful induction of RAI-uptake after treatment with ROSI in a patient with noniodide avid metastases of DTC [109, 110]. Decreased thyroglobulin levels and tumor size indicated partial success of this treatment. Evidence for increased RAI-uptake upon treatment with ROSI was obtained in one of five patients enrolled in a pilot study [111]. In another pilot study, ROSI treatment resulted in positive RAI scans in 4/10 patients and a clinical trial showed increased RAI-uptake in therapeutic ¹³¹I scans in 5/23 patients [112, 113]. Despite reinduction of RAI-uptake in 5/20 patients of another phase II trial, none had a complete or partial response to ROSI after 3 months [114] by RECIST criteria [115]. The status of a current trial (NCT00098852) with ROSI for reinduction of radioiodine-uptake is not yet known (http://www.clinicaltrial.gov/). Also the redifferentiating action of PIO is being reassessed in a trial focused on follicular variants of PTC (NCT01655719; http://www.clinicaltrial.gov/). Interpretation of the results is complicated by limited accuracy of the technique of ¹³¹I scans and unknown status of receptor expression of the treated tumors, too low levels of expression by the target cells, inhomogeneity of RAI-uptake into the tumor, and the generally poor correlation between RAI-uptake and clinical remission, all of which may be reasons for lack of efficacy. In addition, observation time of less than one year may not be enough to monitor effects in slow-growing DTC.

8. Conclusion

Current data do not suggest a correlation of clinical efficacy and high PPAR expression according to mRNA and protein expression in tumor samples. This lack of relation could be due to methodical problems of PPAR detection in archived tumor samples and in the complexity of TZD action. First, TZDs show a variety of genomic and nongenomic effects and several antitumor effects occur independent of PPAR. This is particularly obvious in experiments where combination of PPAR agonists and antagonists act synergistically on inhibition of proliferation [116]. Cell specific effects of TZDs are particularly important in cancer because their action on immune cells may antagonize their effects on tumor cells. This suggests that administration of TZDs after tumor initiation may be inefficient or even deleterious and could explain why cancer mortality was increased in the meta-analysis of cancer incidence in patients with TZD treatment. Species-specific action was reported between human and murine endothelial cells where increase of proliferation was seen in the mouse cells and an antiproliferative effect in human cells [117]. Furthermore, TZDs show compound-specificity. TRO and CIGLI acted as antiproliferatives on ovarian cancer cell lines, while ROSI and PIO did not. This could be due to additional targets and/or PPAR independent effects; TRO for instance has stronger Akt/mTOR activity than the other TZDs. Finally, the effect of TZDs is concentration-dependent. Low concentrations of TZDs induced cell cycle arrest, while higher doses (>100 µM) caused apoptosis. Effects at higher concentrations can be explained by transactivation of PPAR by cross-talk between signaling pathways where one receptor activates a receptor for a different ligand. Alternatively, TZDs may activate a specific subunit within a receptor oligomer [118]. As to the concentration, other coactivators may be involved in the effect and different downstream processes may be activated. PPAR agonists can also change the cell’s expression of PPAR to different extents.

Against the background of limitations of traditional as well as new (transgenic) mouse models [119, 120] for human cancer, only efficacy in human trials is included in our final assessment. Use of TZDs in cancer might be therapeutic in prostate cancer and glioma, chemopreventive in colon, lung, and breast cancer, and increase therapeutic efficacy combined with other therapies in thyroid cancer, soft tissue sarcoma, and melanoma.

Conflict of Interests

The authors declare that there is no conflict of interests.

References

S. Malik, P. K. Upadhyaya, and S. Miglani, “Thiazolidinediones: a plethro of biological load,” International Journal of PharmTech Research, vol. 3, no. 1, pp. 62–75, 2011.

J. Youssed and M. Badr, “PPAR ligands,” in Peroxisome Proliferator-Activated Receptors: Discovery and Recent Advances, J. Youssed and M. Badr, Eds., Springer Science+Business Media, New York, NY, USA, 2013.

R. L. Koffarnus, K. A. Wargo, and H. M. Phillippe, “Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus,” Annals of Pharmacotherapy, vol. 47, no. 6, pp. 877–885, 2013.

T. Imchen, J. Manasse, K.-W. Min, and S. J. Baek, “Characterization of PPAR dual ligand MCC-555 in AOM-induced colorectal tumorigenesis,” Experimental and Toxicologic Pathology, vol. 65, no. 6, pp. 919–924, 2013.

E. Mylona, I. Giannopoulou, K. Diamantopoulou et al., “Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome,” European Journal of Surgical Oncology, vol. 35, no. 2, pp. 197–201, 2009.

S. Nomura, A. Nakajima, S. Ishimine, N. Matsuhashi, T. Kadowaki, and M. Kaminishi, “Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 3, pp. 443–448, 2006.

I. Papadaki, E. Mylona, I. Giannopoulou, S. Markaki, A. Keramopoulos, and L. Nakopoulou, “PPARγ expression in breast cancer: clinical value and correlation with ERβ,” Histopathology, vol. 46, no. 1, pp. 37–42, 2005.

G. Y. Zhang, N. Ahmed, C. Riley et al., “Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma,” British Journal of Cancer, vol. 92, no. 1, pp. 113–119, 2005.

L. Yao, F. Liu, L. Sun et al., “Upregulation of PPARγ in tissue with gastric carcinoma,” Hybridoma, vol. 29, no. 4, pp. 341–343, 2010.

M. Pancione, L. Sabatino, A. Fucci et al., “Epigenetic silencing of peroxisome proliferator- activated receptor γ is a biomarker for colorectal cancer progression and adverse patients’ outcome,” PLoS ONE, vol. 5, no. 12, Article ID e14229, 2010.

S. Ogino, K. Shima, Y. Baba et al., “Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis,” Gastroenterology, vol. 136, no. 4, pp. 1242–1250, 2009.

M. Nickkho-Amiry, R. McVey, and C. Holland, “Peroxisome proliferator-activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma,” Molecular Cancer Research, vol. 10, no. 3, pp. 441–453, 2012.

C. K. Glass and K. Saijo, “Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells,” Nature Reviews Immunology, vol. 10, no. 5, pp. 365–376, 2010.

M. J. Pishvaian, J. L. Marshall, A. J. Wagner et al., “A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies,” Cancer, vol. 118, no. 21, pp. 5403–5413, 2012.

X. Sun, J. D. Ritzenthaler, Y. Zheng, J. Roman, and S. Han, “Rosiglitazone inhibits α4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor γ-independent signals,” Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 110–118, 2009.

F. Chen and L. E. Harrison, “Ciglitazone-induced cellular anti-proliferation increases p27 kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation,” Cellular Signalling, vol. 17, no. 7, pp. 809–816, 2005.

D. Panigrahy, S. Singer, L. Q. Shen et al., “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002.

B. Shen, E. S. H. Chu, G. Zhao et al., “PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice,” British Journal of Cancer, vol. 106, no. 9, pp. 1486–1494, 2012.

A. Galli, E. Ceni, D. W. Crabb et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms,” Gut, vol. 53, no. 11, pp. 1688–1697, 2004.

P. E. Moss, B. E. Lyles, and L. V. Stewart, “The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells,” Experimental Cell Research, vol. 316, no. 20, pp. 3478–3488, 2010.

B. E. Lyles, T. O. Akinyeke, P. E. Moss, and L. V. Stewart, “Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARγ-dependent and PPARγ-independent pathways,” Cell Cycle, vol. 8, no. 2, pp. 268–277, 2009.

A. Mantovani and A. Sica, “Macrophages, innate immunity and cancer: balance, tolerance, and diversity,” Current Opinion in Immunology, vol. 22, no. 2, pp. 231–237, 2010.

R. Seger and E. G. Krebs, “The MAPK signaling cascade,” FASEB Journal, vol. 9, no. 9, pp. 726–735, 1995.

E. Burgermeister and R. Seger, “PPARγ and MEK interactions in cancer,” PPAR Research, vol. 2008, Article ID 309469, 16 pages, 2008.

X. Li, X. Yang, Y. Xu, X. Jiang, F. Nan, and H. Tang, “Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor γ,” Cell Research, vol. 19, no. 6, pp. 720–732, 2009.

M. Dall’Asta, E. Derlindati, D. Ardigò, I. Zavaroni, F. Brighenti, and D. Del Rio, “Macrophage polarization: the answer to the diet/inflammation conundrum?” Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 5, pp. 387–392, 2012.

F. Meisner, D. Walcher, F. Gizard et al., “Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 4, pp. 845–850, 2006.

C. Ao, Y. Huo, L. Qi, Z. Xiong, L. Xue, and Y. Qi, “Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-κB,” Cell Biology International, vol. 34, no. 7, pp. 723–730, 2010.

E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, and R. Seger, “Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ,” Molecular and Cellular Biology, vol. 27, no. 3, pp. 803–817, 2007.

R. E. Nakles, B. V. S. Kallakury, and P. A. Furth, “The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency,” The American Journal of Pathology, vol. 182, no. 6, pp. 1976–1985, 2013.

N. Shimazaki, N. Togashi, M. Hanai et al., “Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model,” European Journal of Cancer, vol. 44, no. 12, pp. 1734–1743, 2008.

G. D. Demetri, C. D. Fletcher, E. Mueller et al., “Induction of solid tumor differentiation by the peroxisome proliferator- activated receptor-γ ligand troglitazone in patients with liposarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3951–3956, 1999.

G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debiec-Rychter, R. Oyen, and A. van Oosterom, “A phase II trial with rosiglitazone in liposarcoma patients,” British Journal of Cancer, vol. 89, no. 8, pp. 1409–1412, 2003.

Y. Dai and W. H. Wang, “Peroxisome proliferator-activated receptor gamma and colorectal cancer,” World Journal of Gastrointestinal Oncology, vol. 2, no. 3, pp. 159–164, 2010.

M. Pancione, N. Forte, L. Sabatino et al., “Reduced β-catenin and peroxisome proliferator-activated receptor-γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome,” Human Pathology, vol. 40, no. 5, pp. 714–725, 2009.

S. Theocharis, C. Giaginis, A. Parasi et al., “Expression of peroxisome proliferator-activated receptor-γ in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients’ survival,” Digestive Diseases and Sciences, vol. 52, no. 9, pp. 2305–2311, 2007.

A. Gustafsson, E. Hansson, U. Kressner et al., “EP1-4 subtype, COX and PPARγ receptor expression in colorectal cancer in prediction of disease-specific mortality,” International Journal of Cancer, vol. 121, no. 2, pp. 232–240, 2007.

C. A. McAlpine, Y. Barak, I. Matise, and R. T. Cormier, “Intestinal-specific PPARγ deficiency enhances tumorigenesis in ApcMin/+ mice,” International Journal of Cancer, vol. 119, no. 10, pp. 2339–2346, 2006.

E. Osawa, A. Nakajima, K. Wada et al., “Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice,” Gastroenterology, vol. 124, no. 2, pp. 361–367, 2003.

T. Yoshizumi, T. Ohta, I. Ninomiya et al., “Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects,” International Journal of Oncology, vol. 25, no. 3, pp. 631–639, 2004.

I. K. Choi, Y. H. Kim, J. S. Kim, and J. H. Seo, “PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo,” Investigational New Drugs, vol. 26, no. 3, pp. 283–288, 2008.

T. Tsukahara and H. Haniu, “Peroxisome proliferator-activated receptor gamma overexpression suppresses proliferation of human colon cancer cells,” Biochemical and Biophysical Research Communications, vol. 424, no. 3, pp. 524–529, 2012.

M. H. Kulke, G. D. Demetri, N. E. Sharpless et al., “A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer,” Cancer Journal, vol. 8, no. 5, pp. 395–399, 2002.

S. Theocharis, H. Kanelli, E. Politi et al., “Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade,” Lung Cancer, vol. 36, no. 3, pp. 249–255, 2002.

H. Sasaki, M. Tanahashi, H. Yukiue et al., “Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer,” Lung Cancer, vol. 36, no. 1, pp. 71–76, 2002.

C. M. Lyon, D. M. Klinge, K. C. Do et al., “Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model,” Carcinogenesis, vol. 30, no. 12, pp. 2095–2099, 2009.

W. G. Jiang, A. Douglas-Jones, and R. E. Mansel, “Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes,” International Journal of Cancer, vol. 106, no. 5, pp. 752–757, 2003.

G. Magenta, X. Borenstein, R. Rolando, and M. A. Jasnis, “Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3,” BMC Cancer, vol. 8, article 47, 2008.

B. Bojková, M. Garajová, K. Kajo et al., “Pioglitazone in chemically induced mammary carcinogenesis in rats,” European Journal of Cancer Prevention, vol. 19, no. 5, pp. 379–384, 2010.

H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, “Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study,” Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 391–397, 2003.

L. D. Yee, N. Williams, P. Wen et al., “Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers,” Clinical Cancer Research, vol. 13, no. 1, pp. 246–252, 2007.

Y. Nakamura, T. Suzuki, A. Sugawara, Y. Arai, and H. Sasano, “Peroxisome proliferator-activated receptor gamma in human prostate carcinoma,” Pathology International, vol. 59, no. 5, pp. 288–293, 2009.

J.-S. Annicotte, I. Iankova, S. Miard et al., “Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer,” Molecular and Cellular Biology, vol. 26, no. 20, pp. 7561–7574, 2006.

E. Mueller, M. Smith, P. Sarraf et al., “Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10990–10995, 2000.

J. I. Hisatake, T. Ikezoe, M. Carey, S. Holden, S. Tomoyasu, and H. P. Koeffler, “Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer,” Cancer Research, vol. 60, no. 19, pp. 5494–5498, 2000.

M. Kato, T. Nagaya, M. Fujieda, K. Saito, J. Yoshida, and H. Seo, “Expression of PPARγ and its ligand-dependent growth inhibition in human brain tumor cell lines,” Japanese Journal of Cancer Research, vol. 93, no. 6, pp. 660–666, 2002.

C. Grommes, D. S. Conway, A. Alshekhlee, and J. S. Barnholtz-Sloan, “Inverse association of PPARγ agonists use and high grade glioma development,” Journal of Neuro-Oncology, vol. 100, no. 2, pp. 233–239, 2010.

C. Grommes, J. C. Karlo, A. Caprariello, D. Blankenship, A. Dechant, and G. E. Landreth, “The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model,” Cancer Chemotherapy and Pharmacology, vol. 71, no. 4, pp. 929–936, 2013.

P. Hau, L. Kunz-Schughart, U. Bogdahn et al., “Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study,” Oncology, vol. 73, no. 1-2, pp. 21–25, 2007.

S. Meyer, T. Vogt, M. Landthaler et al., “Research article: Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma,” PPAR Research, vol. 2010, Article ID 848645, 10 pages, 2010.

A. Ferrara, J. D. Lewis, C. P. Quesenberry Jr. et al., “Cohort study of pioglitazone and cancer incidence in patients with diabetes,” Diabetes Care, vol. 34, no. 4, pp. 923–929, 2011.

T. Botton, A. Puissant, P. Bahadoran et al., “In vitro and in vivo anti-melanoma effects of ciglitazone,” Journal of Investigative Dermatology, vol. 129, no. 5, pp. 1208–1218, 2009.

R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1476–1481, 2007.

M. Monami, I. Dicembrini, and E. Mannucci, “Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials,” Acta Diabetologica, vol. 51, no. 1, pp. 91–101, 2014.

S. Kawa, T. Nikaido, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone,” Pancreas, vol. 24, no. 1, pp. 1–7, 2002.

M. Kato, T. Kusumi, S. Tsuchida, M. Tanaka, M. Sasaki, and H. Kudo, “Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 2, pp. 73–79, 2004.

I. Jagan, A. Fatehullah, R. K. Deevi, V. Bingham, and F. C. Campbell, “Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPARγ-targeted therapy,” Oncogene, vol. 32, no. 10, pp. 1305–1315, 2013.

Y. Li, Y. Meng, H. Li et al., “Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375,” Medical Oncology, vol. 23, no. 3, pp. 393–402, 2006.

A. Aiello, G. Pandini, F. Frasca et al., “Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells,” Endocrinology, vol. 147, no. 9, pp. 4463–4475, 2006.

E. Pestereva, S. Kanakasabai, and J. J. Bright, “PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells,” British Journal of Cancer, vol. 106, no. 10, pp. 1702–1712, 2012.

C. L. Varley, J. Stahlschmidt, B. Smith, M. Stower, and J. Southgate, “Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells,” The American Journal of Pathology, vol. 164, no. 5, pp. 1789–1798, 2004.

M.-Y. Li, A. W. Y. Kong, H. Yuan et al., “Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice,” Current Cancer Drug Targets, vol. 12, no. 6, pp. 597–606, 2012.

I. Borbath, I. Leclercq, P. Moulin, C. Sempoux, and Y. Horsmans, “The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver,” European Journal of Cancer, vol. 43, no. 11, pp. 1755–1763, 2007.

J. Yu, L. Qiao, L. Zimmermann et al., “Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo,” Hepatology, vol. 43, no. 1, pp. 134–143, 2006.

W. Wu, J. Celestino, M. R. Milam et al., “Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model,” International Journal of Gynecological Cancer, vol. 18, no. 2, pp. 329–338, 2008.

S. Theocharis, J. Klijanienko, C. Giaginis et al., “Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 2, pp. 251–259, 2011.

R. Suzuki, H. Kohno, M. Suzui et al., “An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies,” Carcinogenesis, vol. 27, no. 3, pp. 619–630, 2006.

K. Yoshida, Y. Hirose, T. Tanaka et al., “Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor γ ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide,” Cancer Science, vol. 94, no. 4, pp. 365–371, 2003.

H. Li, A. L. Sorenson, J. Poczobutt et al., “Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis,” PLoS ONE, vol. 6, no. 12, Article ID e28133, 2011.

D. Bonofiglio, E. Cione, H. Qi et al., “Combined low doses of PPARγ and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells,” The American Journal of Pathology, vol. 175, no. 3, pp. 1270–1280, 2009.

P. Tontonoz, S. Singer, B. M. Forman et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 237–241, 1997.

L. Q. Cao, X. L. Wang, Q. Wang et al., “Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway,” Acta Pharmacologica Sinica, vol. 30, no. 9, pp. 1316–1322, 2009.

S. Y. Lee, G. Y. Hur, K. H. Jung et al., “PPAR-γ agonist increase gefitinib’s antitumor activity through PTEN expression,” Lung Cancer, vol. 51, no. 3, pp. 297–301, 2006.

Z. Yang, R. Bagheri-Yarmand, S. Balasenthil et al., “HER2 regulation of peroxisome proliferator-activated receptor γ (PPARγ) expression and sensitivity of breast cancer cells to PPARγ ligand therapy,” Clinical Cancer Research, vol. 9, no. 8, pp. 3198–3203, 2003.

G. D. Girnun, E. Naseri, S. B. Vafai et al., “Synergy between PPARγ ligands and platinum-based drugs in cancer,” Cancer Cell, vol. 11, no. 5, pp. 395–406, 2007.

K. Tikoo, P. Kumar, and J. Gupta, “Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats,” BMC Cancer, vol. 9, article 107, 2009.

N. Hamaguchi, H. Hamada, S. Miyoshi et al., “In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth,” Cancer Science, vol. 101, no. 9, pp. 1955–1964, 2010.

J. A. Copland, L. A. Marlow, S. Kurakata et al., “Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006.

Y. Yokoyama, B. Xin, T. Shigeto, and H. Mizunuma, “Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 8, pp. 1219–1228, 2011.

H. Fu, J. Zhang, J. Pan et al., “Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice,” Molecular Carcinogenesis, vol. 50, no. 12, pp. 913–921, 2011.

A. Reichle, K. Bross, T. Vogt et al., “Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma,” Cancer, vol. 101, no. 10, pp. 2247–2256, 2004.

T. Vogt, C. Hafner, K. Bross et al., “Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors,” Cancer, vol. 98, no. 10, pp. 2251–2256, 2003.

F. Ondrey, “Peroxisome proliferator-activated receptor γ pathway targeting in carcinogenesis: implications For Chemoprevention,” Clinical Cancer Research, vol. 15, no. 1, pp. 2–8, 2009.

O. Omur and Y. Baran, “An update on molecular biology of thyroid cancers,” Critical Reviews in Oncology/Hematology, vol. 90, no. 3, pp. 233–252, 2014.

N. Li, X. L. Du, L. R. Reitzel, L. Xu, and E. M. Sturgis, “Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008,” Thyroid, vol. 23, no. 1, pp. 103–110, 2013.

C. F. A. Eustatia-Rutten, E. P. M. Corssmit, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. W. Smit, “Survival and death causes in differentiated thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 313–319, 2006.

C. Durante, N. Haddy, E. Baudin et al., “Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 2892–2899, 2006.

O. Dohán, A. De La Vieja, V. Paroder et al., “The sodium/iodide symporter (NIS): characterization, regulation, and medical significance,” Endocrine Reviews, vol. 24, no. 1, pp. 48–77, 2003.

M. J. Schlumberger, “Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status,” Journal of Endocrinological Investigation, vol. 22, no. 11, pp. 3–7, 1999.

T. Carling and R. Udelsman, Eds., Thyroid Tumors, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 9th edition, 2011.

A. Versari, M. Sollini, A. Frasoldati et al., “Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients,” Thyroid, vol. 24, no. 4, pp. 715–726, 2014.

M. L. Martelli, R. Iuliano, I. Le Pera et al., “Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 10, pp. 4728–4735, 2002.

E. Fröhlich, P. Brossart, and R. Wahl, “Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 5, pp. 780–790, 2009.

J.-W. Park, R. Zarnegar, H. Kanauchi et al., “Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines,” Thyroid, vol. 15, no. 3, pp. 222–231, 2005.

E. Fröhlich, F. Machicao, and R. Wahl, “Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture,” Endocrine-Related Cancer, vol. 12, no. 2, pp. 291–303, 2005.

M. E. Dobson, E. Diallo-Krou, V. Grachtchouk et al., “Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARγ fusion protein thyroid carcinoma,” Endocrinology, vol. 152, no. 11, pp. 4455–4465, 2011.

Y. Kato, H. Ying, L. Zhao et al., “PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway,” Oncogene, vol. 25, no. 19, pp. 2736–2747, 2006.

S. J. Rosenbaum-Krumme, A. Bockisch, and J. Nagarajah, “Pioglitazone therapy in progressive differentiated thyroid carcinoma,” NuklearMedizin, vol. 51, no. 4, pp. 111–115, 2012.

M. Elola, A. Yoldi, J. I. Emparanza, T. Matteucci, I. Bilbao, and M. Goena, “Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake,” Revista Espanola de Medicina Nuclear, vol. 30, no. 4, pp. 241–243, 2011.

A. N. Elias and P. Lizotte, “Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone,” Clinical Nuclear Medicine, vol. 31, no. 9, pp. 517–519, 2006.

J.-C. Philips, C. Petite, J.-P. Willi, F. Buchegger, and C. A. Meier, “Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers,” Nuclear Medicine Communications, vol. 25, no. 12, pp. 1183–1186, 2004.

E. Kebebew, M. Peng, E. Reiff et al., “A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer,” Surgery, vol. 140, no. 6, pp. 960–967, 2006.

S. Tepmongkol, S. Keelawat, S. Honsawek, and P. Ruangvejvorachai, “Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma,” Thyroid, vol. 18, no. 7, pp. 697–704, 2008.

E. Kebebew, S. Lindsay, O. H. Clark, K. A. Woeber, R. Hawkins, and F. S. Greenspan, “Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer,” Thyroid, vol. 19, no. 9, pp. 953–956, 2009.

E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009.

J. D. Burton, D. M. Goldenberg, and R. D. Blumenthal, “Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types,” PPAR Research, vol. 2008, Article ID 494161, 7 pages, 2008.

S. Kakiuchi-Kiyota, J. A. Vetro, S. Suzuki et al., “Effects of the PPARγ agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse,” Toxicology and Applied Pharmacology, vol. 237, no. 1, pp. 83–90, 2009.

S. Takano, T. Kubota, H. Nishibori et al., “Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis,” Anticancer Research, vol. 28, no. 6, pp. 3593–3599, 2008.

S. J. Diede, Z. Yao, C. Chip Keyes et al., “Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer,” Epigenetics, vol. 8, no. 12, pp. 1254–1260, 2013.

M. De Jong and T. Maina, “Of mice and humans: are they the same?—Implications in cancer translational research,” Journal of Nuclear Medicine, vol. 51, no. 4, pp. 501–504, 2010.

V. Vaish, L. Tanwar, and S. N. Sanyal, “The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors,” Tumour Biology, vol. 31, no. 5, pp. 427–436, 2010.

M. V. Pino, M. F. Kelley, and Z. Jayyosi, “Promotion of colon tumors in C57BL/6J-APCmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist,” Toxicologic Pathology, vol. 32, no. 1, pp. 58–63, 2004.

H. Kohno, S. Yoshitani, S. Takashima et al., “Troglitazone, a ligand for peroxisome proliferator-activated receptor γ, inhibits chemically-induced aberrant crypt foci in rats,” Japanese Journal of Cancer Research, vol. 92, no. 4, pp. 396–403, 2001.

E. J. Han, C. N. Im, S. H. Park, E. Y. Moon, and S. H. Hong, “Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells,” International Journal of Radiation Oncology Biology Physics, vol. 85, no. 5, pp. e239–e248, 2013.

S. Y. James, F. Lin, S. K. Kolluri, M. I. Dawson, and X.-K. Zhang, “Regulation of retinoic acid receptor β expression by peroxisome proliferator-activated receptor γ ligands in cancer cells,” Cancer Research, vol. 63, no. 13, pp. 3531–3538, 2003.

A. Papi, P. Rochhi, A. M. Ferreri, F. Guerra, and M. Orlandi, “Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells,” Oncology Reports, vol. 21, no. 4, pp. 1083–1089, 2009.

A. Papi, L. Tatenhorst, D. Terwel et al., “PPARγ and RXRγ ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models,” Journal of Neurochemistry, vol. 109, no. 6, pp. 1779–1790, 2009.

K. Bräutigam, J. Biernath-Wüpping, D. O. Bauerschlag et al., “Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5, pp. 875–886, 2011.

P. Mrówka, E. Glodkowska, D. Nowis et al., “Ciglitazone, an agonist of peroxisome proliferator-activated receptor γ, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin,” International Journal of Oncology, vol. 32, no. 1, pp. 249–255, 2008.

T. H. Chang and E. Szabo, “Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung,” Clinical Cancer Research, vol. 8, no. 4, pp. 1206–1212, 2002.

Y. Liu, Z.-A. Zhu, S.-N. Zhang et al., “Combinational effect of PPARγ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro,” Tumor Biology, vol. 34, no. 4, pp. 2409–2418, 2013.

R. C. Reddy, A. Srirangam, K. Reddy et al., “Chemotherapeutic drugs induce PPAR-γ expression and show sequence-specific synergy with PPAR-γ ligands in inhibition of non-small cell lung cancer,” Neoplasia, vol. 10, no. 6, pp. 597–603, 2008.

E. Elstner, E. A. Williamson, C. Zang et al., “Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells,” Breast Cancer Research and Treatment, vol. 74, no. 2, pp. 155–165, 2002.

B.-H. Park, S.-B. Lee, D. B. Stolz, Y. J. Lee, and B.-C. Lee, “Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-γ (PPARγ) agonist in breast cancer cells,” Journal of Biological Chemistry, vol. 286, no. 22, pp. 20087–20099, 2011.

C.-J. Yao, G.-M. Lai, C.-F. Chan, A.-L. Cheng, Y.-Y. Yang, and S.-E. Chuang, “Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone,” International Journal of Cancer, vol. 118, no. 3, pp. 773–779, 2006.

K.-H. Yan, C.-J. Yao, H.-Y. Chang, G.-M. Lai, A.-L. Cheng, and S.-E. Chuang, “The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells,” Molecular Carcinogenesis, vol. 49, no. 3, pp. 235–246, 2010.

H.-N. Yu, E.-M. Noh, Y.-R. Lee et al., “Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells,” Biochemical and Biophysical Research Communications, vol. 377, no. 1, pp. 242–247, 2008.

Z. An, X. Liu, H. Song et al., “Effect of troglitazone on radiation sensitivity in cervix cancer cells,” Radiation Oncology Journal, vol. 30, no. 2, pp. 78–87, 2012.

Y.-Q. Zhang, X.-Q. Tang, L. Sun et al., “Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor γ,” World Journal of Gastroenterology, vol. 13, no. 10, pp. 1534–1540, 2007.

R. M. Cesario, J. Stone, W.-C. Yen, R. P. Bissonnette, and W. W. Lamph, “Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer,” Cancer Letters, vol. 240, no. 2, pp. 225–233, 2006.

M. Mody, N. Dharker, M. Bloomston et al., “Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-α, CH11 and CYC202,” Endocrine-Related Cancer, vol. 14, no. 2, pp. 305–315, 2007.

H. Koga, K. Selvendiran, R. Sivakumar et al., “PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells,” International Journal of Oncology, vol. 40, no. 3, pp. 679–685, 2012.

C. Freudlsperger, A. Thies, U. Pfuller, and U. Schumacher, “The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-γ agonist rosiglitazone in human melanoma cells,” Anticancer Research, vol. 27, no. 1, pp. 207–213, 2007.

S. Gehring, J. H. Tapia-Pérez, E. Kirches et al., “Cytotoxic effects of statins and thiazolidinediones on meningioma cells,” Journal of Neuro-Oncology, vol. 102, no. 3, pp. 383–393, 2011.

J. H. Tapia-Pérez, E. Kirches, C. Mawrin, R. Firsching, and T. Schneider, “Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 5, pp. 1193–1201, 2011.

E. Gottfried, S. Rogenhofer, H. Waibel et al., “Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 1, pp. 117–126, 2011.